197 related articles for article (PubMed ID: 8655274)
1. [Immunotherapy with genetically modified tumor cells].
Topf N; Schmiegel WH
Internist (Berl); 1996 Apr; 37(4):374-81. PubMed ID: 8655274
[No Abstract] [Full Text] [Related]
2. Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines.
Jaffee EM; Pardoll DM
Methods; 1997 Jun; 12(2):143-53. PubMed ID: 9184378
[TBL] [Abstract][Full Text] [Related]
3. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer.
Song K; Chang Y; Prud'homme GJ
Gene Ther; 2000 Mar; 7(6):481-92. PubMed ID: 10757021
[TBL] [Abstract][Full Text] [Related]
4. More about genetically modified tumour vaccines.
Mackiewicz A; Rose-John S
Gene Ther; 1998 Feb; 5(2):147-8. PubMed ID: 9578832
[No Abstract] [Full Text] [Related]
5. Genetic modification of T cells improves the effectiveness of adoptive tumor immunotherapy.
Jakóbisiak M; Gołab J
Arch Immunol Ther Exp (Warsz); 2010 Oct; 58(5):347-54. PubMed ID: 20694520
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy for malignant glioblastoma].
Nose T; Nakagawa K
No Shinkei Geka; 1995 Mar; 23(3):195-206. PubMed ID: 7700486
[No Abstract] [Full Text] [Related]
7. Cytokine gene transfer in cancer therapy.
Cao L; Kulmburg P; Veelken H; Mackensen A; Mézes B; Lindemann A; Mertelsmann R; Rosenthal FM
Stem Cells; 1998; 16 Suppl 1():251-60. PubMed ID: 11012169
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cell-based immunotherapy in cancer: current insights and future prospects.
Sutlu T; Alici E
J Intern Med; 2009 Aug; 266(2):154-81. PubMed ID: 19614820
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of tumor metastasis via gene therapy.
Porgador A; Feldman M; Eisenbach L
Nat Immun; 1994; 13(2-3):113-30. PubMed ID: 8173233
[TBL] [Abstract][Full Text] [Related]
10. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
11. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
Loskog A; Tötterman TH; Böhle A; Brandau S
Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
[TBL] [Abstract][Full Text] [Related]
12. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer.
Lamers CH; Willemsen RA; Luider BA; Debets R; Bolhuis RL
Cancer Gene Ther; 2002 Jul; 9(7):613-23. PubMed ID: 12082462
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunogene therapy.
Yoshizawa H; Kagamu H; Gejyo F
Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
[TBL] [Abstract][Full Text] [Related]
14. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models.
Hiroishi K; Tüting T; Tahara H; Lotze MT
Gene Ther; 1999 Dec; 6(12):1988-94. PubMed ID: 10637450
[TBL] [Abstract][Full Text] [Related]
15. [Vaccine therapy for brain tumors using tumor cells genetically modified to express B7.1].
Kajiwara K; Morioka J; Yoshikawa K; Suzuki M
Nihon Rinsho; 2005 Sep; 63 Suppl 9():578-81. PubMed ID: 16201584
[No Abstract] [Full Text] [Related]
16. Targeting gene therapy--a reality?
Dranoff G
Mol Ther; 2000 Feb; 1(2):117-8. PubMed ID: 10933921
[No Abstract] [Full Text] [Related]
17. Immunological approach to gene therapy of human cancer: improvements through the understanding of mechanism(s).
Parmiani G
Gene Ther; 1998 Jul; 5(7):863-4. PubMed ID: 9813655
[No Abstract] [Full Text] [Related]
18. Molecular approaches to cancer immunotherapy.
Forni G; Cavallo F; Consalvo M; Allione A; Dellabona P; Casorati G; Giovarelli M
Cytokines Mol Ther; 1995 Dec; 1(4):225-48. PubMed ID: 9384678
[TBL] [Abstract][Full Text] [Related]
19. DNA and RNA modified dendritic cell vaccines.
Morse MA; Lyerly HK
World J Surg; 2002 Jul; 26(7):819-25. PubMed ID: 11948364
[TBL] [Abstract][Full Text] [Related]
20. Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function.
Landmeier S; Altvater B; Pscherer S; Eing BR; Kuehn J; Rooney CM; Juergens H; Rossig C
Cancer Res; 2007 Sep; 67(17):8335-43. PubMed ID: 17804749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
